LRC-CPPTLipid Research Clinics Study Coronary Primary Prevention Trial
References in periodicals archive ?
LRC-CPPT was a double-blind, placebo-controlled trial of the effects of cholestyramine on the prevention of CAD in 3,806 men with primary hypercholesterolemia.
LRC-CPPT, which compared cardiovascular outcomes in 3,806 men treated double-blind with BAS or placebo, was one of the first large studies to definitively associate a reduction in LDL-C with a reduction in CAD risk.
Bile acid sequestrant monotherapy: summary of serum lipid effects from clinical trials Study Study Agent Dosage N duration LRC-CPPT Cholestyramine 4-8 g/d (b) 3806 7.